source
- BridgeBio eyes first FDA approval for limb-girdle muscular dystrophy therapyBridgeBio Pharma is preparing for a potential launch of its experimental drug BBP-418 aimed at treating limb-girdle muscular dystrophy type 2I/R9, pending FDA decision. The agency has set a review…
- FDA approves generic lenacapavir for low-income markets; EMA to review Lundbeck's Deanxit over safety concernsThe U.S. Food and Drug Administration has granted approval for a generic version of lenacapavir, a drug aimed at treating HIV, with the intention of making it available to lower-income countries.…